Poseida Therapeutics, Inc. (PSTX)

Market Cap	276.92M
Revenue (ttm)	64.70M
Net Income (ttm)	-123.43M
Shares Out	96.49M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	546,780
Open	2.830
Previous Close	2.790
Day's Range	2.820 - 2.990
52-Week Range	1.540 - 4.270
Beta	0.36
Analysts	Strong Buy
Price Target	14.67 (+411.15%)
Earnings Date	May 14, 2024

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple my...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 330
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTX

Financial Performance

In 2023, PSTX's revenue was $64.70 million, a decrease of -50.42% compared to the previous year's $130.49 million. Losses were -$123.43 million, 92.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 411.15% from the latest price.

Price Target

$14.67

(411.15% upside)

Analyst Consensus: Strong Buy